UKCGG Consensus Group guidelines for the management of patients with constitutional <i>TP53</i> pathogenic variants.
expert_opinion · Level V
Where this comes from
- Record sourced from PubMed, PMID 32571901.
- Also identified by DOI 10.1136/jmedgenet-2020-106876 and PMC identifier 7848057.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Constitutional pathogenic variants in <i>TP53</i> are associated with Li-Fraumeni syndrome or the more recently described heritable <i>TP53-</i>related cancer syndrome and are associated with increased lifetime risks of a wide spectrum of cancers. Due to the broad tumour spectrum, surveillance for this patient group has been limited. To date, the only recommendation in the UK has been for annual breast MRI in women; however, more recently, a more intensive surveillance protocol including whole-body MRI (WB-MRI) has been recommended by International Expert Groups. To address the gap in surveillance for this patient group in the UK, the UK Cancer Genetics Group facilitated a 1-day consensus meeting to discuss a protocol for the UK. Using a preworkshop survey followed by structured discussion on the day, we achieved consensus for a UK surveillance protocol for <i>TP53</i> carriers to be adopted by UK Clinical Genetics services. The key recommendations are for annual WB-MRI and dedicated brain MRI from birth, annual breast MRI from 20 years in women and three-four monthly abdominal ultrasound in children along with review in a dedicated clinic.